Galactosemia type II, also known as galactokinase deficiency, is an autosomal recessive hereditary disorder of galactose metabolism caused by variants in the GALK1 gene. The reduced or absent activity of galactokinase prevents the normal utilization of this sugar and favors the accumulation of galactose and galactitol, which primarily manifests as neonatal or infantile onset cataracts.
Galactosemia type 2 (GALK1 gene)
The GALK1 gene provides instructions for making the enzyme galactokinase 1, a cytosolic protein that catalyzes the first step of the Leloir pathway, the main metabolic route for transforming galactose into usable intermediates as an energy source. Its function is to phosphorylate galactose and convert it into galactose-1-phosphate, allowing the metabolism of this sugar to proceed in an orderly manner.
When pathogenic variants exist in GALK1, galactokinase activity is markedly reduced or completely lost. Unmetabolized galactose accumulates in the blood and urine, and some of it is converted by alternative pathways into galactitol, an osmotically active compound. The accumulation of galactitol in the lens is the primary mechanism for cataract formation. Unlike classic galactosemia due to GALT deficiency, galactosemia type II typically has a milder course and is not typically associated with liver failure, neonatal sepsis, or acute neurological damage. However, rare extraocular manifestations have been described, so clinical follow-up is recommended. Inheritance is autosomal recessive, and the disease requires two pathogenic variants in GALK1. It is a rare condition, with variable prevalence depending on the population, and shows a higher frequency in some Romani groups in Europe due to founder effect.
Symptoms
Galactosemia type II can be detected in newborn screening by elevated galactose or manifest during the first weeks or months of life. The most characteristic clinical sign, and often the only one, is bilateral cataracts, which can cause lens opacity and vision impairment if left untreated. Neurological development is usually normal, and severe hepatopathy or the typical systemic complications of galactosemia type I are not common. With early diagnosis and dietary restriction, cataracts can be prevented or even improved; if they persist, they may require ophthalmological evaluation and surgical treatment.
Disease management
Management is based on reducing exposure to galactose and lactose from diagnosis, especially during breastfeeding and early childhood, to prevent galactitol formation in the lens. Dietary intervention must be supervised by specialists in metabolism and nutrition, with substitution of milk and dairy products for appropriate formulas or foods. Follow-up includes biochemical monitoring of galactose and its metabolites, regular ophthalmological check-ups, and monitoring of growth and nutritional status. There is no specific enzymatic or pharmacological therapy; when cataracts do not resolve with diet, surgery may be necessary.
Genes analyzed
Bibliography
P S, Ebrahimi EA, Ghazala SA, et al. Structural analysis of missense mutations in galactokinase 1 (GALK1) leading to galactosemia type-2. J Cell Biochem. 2018 Sep;119(9):7585-7598.
Timson DJ. The molecular basis of galactosemia - Past, present and future. Gene. 2016 Sep 10;589(2):133-41.
Iwasawa S, Kikuchi A, Wada Y, et al. The prevalence of GALM mutations that cause galactosemia: A database of functionally evaluated variants. Mol Genet Metab. 2019 Apr;126(4):362-367.
